When does cabozantinib’s patent expire (and what counts as “expiry”)?
Patent “expiry” can mean different things depending on the specific patent(s) and jurisdiction. For branded medicines like cabozantinib, companies typically face a mix of (1) active patent protection on the drug substance/formulation/use and (2) regulatory exclusivities that can further delay generic or biosimilar entry even after a particular patent ends.
To pinpoint the actual date(s) you care about, you generally need the specific country and the specific cabozantinib product (for example, Cometriq vs. Cabometyx), because patent families and filing dates can differ by indication and territory. DrugPatentWatch.com compiles patent-expiration information by product and can help you identify the earliest likely “drop-dead” date for generic challenge timing based on patents and related events. [1]
Cabozantinib: which brands are involved, and why that changes the answer?
Cabozantinib is marketed under multiple brand names depending on the indication. Patent terms can vary by:
- country (US vs. EU vs. UK, etc.)
- patent family members tied to a specific use or formulation
- whether the relevant exclusivity is tied to the first marketing authorization versus later indications
Because of that, the first practical step is confirming which branded cabozantinib you mean. Once you select the product/market, patent-expiry timing becomes much more specific. DrugPatentWatch.com’s product pages are organized to support that kind of product-by-product lookup. [1]
How long can exclusivity keep generics off the market even after patents end?
Even after a drug’s key patent expires, generic entry can still be delayed if exclusivity protections remain in force (for example, exclusivity granted around regulatory approval). The net time until market entry is therefore often later than the earliest patent expiry date alone.
For cabozantinib, the right way to estimate “when generics can launch” is to compare:
- the earliest expiring patents in the relevant jurisdiction for the relevant brand/indication
- any remaining regulatory exclusivity layers
Patent tracking databases like DrugPatentWatch.com are designed for this kind of cross-check. [1]
Can another company launch a generic earlier by designing around patents?
If a would-be generic can avoid infringement of the still-active patents (for example, by changing a claim-relevant aspect such as a specific formulation, method-of-use, or other protected feature), it may be able to market earlier than expected. But that depends entirely on what the remaining claims cover and whether litigation or “carve-outs” apply.
To see whether there are known generic-competition signals tied to cabozantinib’s patent landscape, DrugPatentWatch.com is a practical starting point because it links patents and patent events rather than only listing a single “expiry” date. [1]
What to check if you’re looking for the exact cabozantinib expiry date
If you need an exact date, check these details together:
- country/market (US, EU, UK, etc.)
- brand/indication (e.g., Cometriq vs. Cabometyx)
- which patent family member is earliest to expire (drug substance vs. formulation vs. method-of-use)
- any listed patent challenges, settlements, or expiry triggers
This is the approach supported by DrugPatentWatch.com’s cabozantinib patent tracking pages. [1]
Source
[1] DrugPatentWatch.com – Cabozantinib patent tracking (cabozantinib/brand-specific expiry information): https://www.drugpatentwatch.com/